← Leaderboards
Sabine Mueller
University Of California, San Francisco
$1,826,791
Attributed
$1,826,791
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $664K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,826,791 · 1
By mechanism
R01$1,826,791 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Nicholas Kostandinos Arger$899,310
- Nader Sanai$5,058,811
- Hideho Okada$20,052,698
- Pavithra Viswanath$6,465,079
- William A Weiss$31,543,847
Others in their field
Other Rising Stars on “Crispr/Cas Technology”
- Christopher W Peterson · Fred Hutchinson Cancer Center$4,692,222
- Xu Chen · University Of California, San Francisco$3,581,285
- Courtney Cohen · Albert Einstein College Of Medicine$3,541,248
- Amar Nijagal · University Of California, San Francisco$3,176,680
- Hao Li · Salk Institute For Biological Studies$2,988,273
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
Research focus
Crispr/Cas TechnologyApoptosisAdultCorrelative StudyBiological MarkersBiological ModelsBiopsyBloodCohortBlood-Brain Barrier PenetrationBlood-Brain Tumor BarrierBrainBrain NeoplasmsCellsCell SurvivalChildChildhoodChildhood Brain NeoplasmBlood - Brain Barrier AnatomyBiological Adaptation To StressClinical DataClinical EfficacyClinical PredictorsDesign
Grant awards (7)
Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors$437,848
R01 · FY2025 · CA · contact PI
Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors$45,321
R01 · FY2025 · CA · contact PI
Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors$36,720
R01 · FY2025 · CA · contact PI
Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors$9,000
R01 · FY2025 · CA · contact PI
Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors$46,752
R01 · FY2024 · CA · contact PI
Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors$587,101
R01 · FY2023 · CA · contact PI
Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors$664,049
R01 · FY2022 · CA · contact PI